EMA acts to improve quality of Type IA variation submissions
This article was originally published in SRA
Executive Summary
The European Medicines Agency is taking steps to improve the quality of applications submitted by pharmaceutical companies seeking to make minor changes (Type IA variations) to their marketing authorisations1. To this end, the EMA has developed a "pre-notification checklist" to help companies submit correct and complete Type IA variation notifications2.